Section Arrow
LYEL.NASDAQ
- Lyell Immunopharma Inc
Quotes are at least 15-min delayed:2026/09/04 00:26 EDT
Regular Hours
Last
 14.32
-0.635 (-4.25%)
Day High 
15.14 
Prev. Close
14.955 
1-M High
17.15 
Volume 
79.05K 
Bid
13.94
Ask
22.67
Day Low
14.19 
Open
15.11 
1-M Low
12.71 
Market Cap 
366.47M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 14.89 
20-SMA 14.7 
50-SMA 13.99 
52-W High 45 
52-W Low 11.47 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-12.69/-9.76
Enterprise Value
408.40M
Balance Sheet
Book Value Per Share
9.54
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
36.00K
Operating Revenue Per Share
1.98
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
RAREUltragenyx Pharmaceutical14.85-11.68-44.03%-- 
AIMAIM ImmunoTech Inc.0.2337-0.0009-0.38%-- 
ATAIAtaiBeckley Inc7.34-0.01-0.14%-- 
SMMTSummit Therapeutics17.13+2.53+17.33%-- 
IOVAIovance Biotherapeutics8.7+0.08+0.93%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) andother GCC-expressing cancers.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.